VENLO, Netherlands & SAN MATEO, Calif.--(BUSINESS WIRE)--QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.
The merger between South San Francisco-based Blade Therapeutics, which is focused on developing treatments for incurable fibrotic and neurodegenerative diseases, and SPRIM Global Investments affiliate Biotech Acquisition Company, will provide the company with $254.3 million to drive the development of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for idiopathic pulmonary fibrosis.
The FDA has published data outlining the limits of 58 different molecular coronavirus tests—illustrating the ability of each authorized diagnostic to detect smaller and smaller amounts of the virus that causes COVID-19.
CAIAC Fund Management AG (“CAIAC”), as portfolio manager for Biotech Opportunity Fund, a Liechtenstein-based Alternative Investment Fund regulated by the Financial Market Authority of Liechtenstein (the “Fund”) announces, pursuant to the Canadian early warning requirements, that on August 27, 2020, it acquired control and direction over, and the Fund acquired ownership of, an aggregate of 26,363,172 common shares (the “Common Shares”) in the capital of Helix BioPharma Corp. (the “Issuer”), in an off-shore transaction (the “Transaction”). The Common Shares were acquired for consideration valued at approximately CAD $0.50 per Common Share, and aggregate consideration value equal to approximately CAD $13,181,586.
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), is a clinical- stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47, today announced that it has extended its collaboration agreement with Moffitt Cancer Center (“Moffitt”) for an additional year.
RICHMOND HILL, Ontario, May 14, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer (“LDOS001”) will be published at the ASCO 2020 Annual Conference
RICHMOND HILL, Ontario, March 12, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 5,042,016 units of the Company (“Units”) at a price of $1.0332 per Unit, and the concurrent disposition of 1,708,023 shares of the Company’s Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), to a third-party purchaser, representing an 15.5% equity stake in HIO (together with the Units, the “Purchased Securities”), for aggregate gross proceeds of CAD $6,000,000, or $1.19 per Purchased Security.
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it has succes